U.S. Food and Drug Administration
ProTab Labs Offers Solutions for Infant Formula Producers Facing Crisis
To tackle the infant formula crisis, producers can rely on Southern California supplement solutions contract manufacturer ProTab Laboratories to blend custom premixes and produce and package infant formula with a rapid turnaround time, the company stated. “ProTab is in the perfect position as a supplement solution manufacturer and packager to prioritize infant formula production with safety and ...
NPA Responds to Report of Increased, Unintentional Pediatric Melatonin Ingestion
Over the past decade and particularly since the beginning of the COVID-19 pandemic, the use of melatonin supplements to address sleep issues has increased significantly by both adults and children. On Thursday, June 3, the Centers for Disease Control and Prevention (CDC) released a 10-year study that found a sharp increase in the use of ...
Durbin, Braun Introduce Legislation to Mandate Product Listings for Dietary Supplements
U.S. Senate Majority Whip Dick Durbin (D-IL) and U.S. Senator Mike Braun (R-IN) introduced the Dietary Supplement Listing Act of 2022, bipartisan legislation to require dietary supplement manufacturers to list their products with the U.S. Food and Drug Administration (FDA). The Dietary Supplement Listing Act of 2022 would require companies to provide FDA with vital information about their ...
CRN Dismisses FDA Response on N-acetyl-cysteine (NAC)
The Council for Responsible Nutrition (CRN) on March 31 denounced the U.S. Food and Drug Administration’s (FDA) decision regarding the legal status of n-acetyl-cysteine (NAC) as a dietary ingredient. “CRN is extremely disappointed and unconvinced by FDA’s response today that it has chosen to deny CRN’s citizen’s petition while holding out the possibility that it may open ...
NPA Says Mandatory Product Listing is a “Non-Starter” and Amounts to “Pre-Market Approval”
The Natural Products Association (NPA) has issued a statement on the President’s FY 2023 Budget Request to Congress regarding the section on the U.S. Food and Drug Administration (FDA). “FDA’s proposal to include mandatory product listing in their FY23 budget request is a non-starter,” said Dr. Daniel Fabricant, the association’s president and CEO. “Year after ...
NPA Files Citizen’s Petition With FDA on Specific CBD Relief
On Feb. 22, in a Citizen’s Petition to the U.S. Food and Drug Administration (FDA), the Natural Products Association (NPA) requested the FDA either: Determine cannabidiol (CBD) is not excluded from the definition of a dietary supplement under 21 U.S.C. §321(ff)(3)(B) allowing the Commissioner the ability to exercise enforcement discretion in a specific and selective ...
Senate Confirms Robert Califf as FDA Commission, Associations Respond
On Feb.15, the U.S. Senate confirmed Dr. Robert Califf to lead the U.S. Food and Drug Administration (FDA) for a second time in a 50-46 vote. In response to the confirmation, the Natural Products Association (NPA), the Council for Responsible Nutrition (CRN), and the Consumer Healthcare Products Association (CHPA) released the following statements: “This agency ...
ICYMI: NPA’s Fabricant Appears on CBS “The Doctors”
Daniel Fabricant, PhD., president and CEO of the Natural Products Association (NPA) and the former chief regulator of the dietary supplement industry appeared on the CBS show “The Doctors” on February 7, 2022. Fabricant discussed the unintended consequences of legislation in California that would place age restrictions on nutritional supplements. The legislation recently passed by ...
California Assembly Votes to Restrict Access to Supplements, NPA Responds
On Jan. 27, the California Assembly passed legislation by a vote of 44-12 that would place age restrictions on nutritional supplements and impose costly burdens on small businesses. The bill will now go through the committee process in the California Senate. The Natural Products Association (NPA) warns that the bill will lead to unintended consequences that include ...
TopGum Triples Capacity With $30M Investment in New Plant
Gummy supplement manufacturer TopGum Industries, Ltd. has begun construction of a new, $30 million (U.S.), 11,000m2 plant 1.5 hours south of Tel Aviv, Israel. The facility, joining the company’s existing production plant, is expected to be fully operated in mid-2023 and triple the TopGum’s production capacity. Fully equipped with high-precision manufacturing technology adapted to TopGum’s ...
Don't Miss Out!
Industry Professionals
Stay Informed!
Stay informed about the latest health, nutrition, and wellness developments by signing up for a FREE subscription to Nutrition Industry Executive magazine and digital newsletter.
Once subscribed, you will receive industry insights, product trends, and important news directly to your doorstep and inbox.
Featured Listings:
